How CA 125 is used in routine clinical practice.

Area of Science:

• Oncology
• Clinical Chemistry
• Medical Diagnostics

Background:

• The CA 125 assay is a biomarker primarily associated with ovarian cancer.
• Established clinical utility for CA 125 is limited to monitoring ovarian cancer and preoperative assessment of ovarian masses.

Purpose of the Study:

• To evaluate the appropriateness of CA 125 test indications in clinical practice.
• To identify patterns of CA 125 test utilization and assess adherence to established guidelines.

Main Methods:

• Retrospective audit of all CA 125 assays performed at Institut Central des Hôpitaux Valaisans (ICHV) between August 1993 and December 1995.
• Analysis of patient data to determine the clinical indication for each CA 125 test performed.

Main Results:

• Out of 1057 CA 125 assays across 462 patients, only 57% of tests (for 33% of patients) met the criteria for correct indication (OC monitoring or preoperative assessment).
• A significant proportion of tests (43%) were used for screening in various clinical situations, indicating inappropriate utilization.
• Specifically, 18% of patients were monitored for OC, and 15% were evaluated preoperatively for ovarian masses.

Conclusions:

• The study reveals widespread inappropriate use of the CA 125 test in clinical practice.
• There is a clear need for educational initiatives targeting healthcare providers to promote rational and evidence-based utilization of CA 125 assays.
• Optimizing CA 125 test ordering can improve diagnostic accuracy and resource allocation in oncology.